Reports related to this article:
Project(s): View 1 related project in PECWeb
Plant(s): View 1 related plant in PECWeb
Released October 26, 2022 | GALWAY, IRELAND
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--
Eli Lilly (NYSE:LLY) (Indianapolis, Indiana) has been granted planning permission to construct a 400 million-euro (US$390 million) cell therapy manufacturing plant in County Limerick, Ireland.
The project will involve the construction of numerous buildings at a greenfield site at the Raheen Business and Technology Park, owned by state body Industrial Development Agency (IDA) Ireland. It will revolve around a four-storey manufacturing building of around 18,500 square meters, alongside a two-storey canteen, laboratory and administration complex. It will produce biologic active ingredients for existing products as well as the company's planned Alzheimer portfolio. When completed, the facility will create 300 new jobs for skilled workers, including engineers, scientists and operations personnel. According to IDA Ireland, an estimated 500 jobs will be created during construction.
Dave Riordan, site lead for the new plant, said: "This decision is a very positive milestone in Lilly's plans to invest in Limerick. Having graduated from the University of Limerick myself, I am delighted that Lilly has chosen the city for this major expansion of our global manufacturing footprint. I am confident that Lilly's arrival to Limerick will bring many additional benefits to the local community, the city and the region in the years ahead."
Ireland is an important European manufacturing hub for Lilly, which employs around 2,000 permanent staff in its Irish operations in County Cork, with an additional 500 outsourced and contract staff. The company's first site in Kinsale, County Cork, has grown into a high-technology manufacturing campus that makes active ingredients for Lilly medicines. It has expanded in recent years to become a center for synthetic small molecule active pharmaceutical ingredient (API) commercialisation.
In related Irish pharma sector news, Swiss major Novartis International AG (NYSE:NVS) (Basel, Switzerland) has announced that 400 jobs are to be cut at its Dublin operations as part of a larger, global restructuring. The changes will take place over the next two years at its Global Service Center, which currently employs around 1,000 staff. "Novartis recognises that announcing such an intention has a significant impact on people and creates uncertainty," the company said in a statement. "Novartis is committed to keeping associates informed in as transparent and timely a manner as possible."
In June, the company announced that in an effort to become "leaner and simpler," it would be cutting 8,000 jobs from its global workforce of 108,000 people.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
The project will involve the construction of numerous buildings at a greenfield site at the Raheen Business and Technology Park, owned by state body Industrial Development Agency (IDA) Ireland. It will revolve around a four-storey manufacturing building of around 18,500 square meters, alongside a two-storey canteen, laboratory and administration complex. It will produce biologic active ingredients for existing products as well as the company's planned Alzheimer portfolio. When completed, the facility will create 300 new jobs for skilled workers, including engineers, scientists and operations personnel. According to IDA Ireland, an estimated 500 jobs will be created during construction.
Dave Riordan, site lead for the new plant, said: "This decision is a very positive milestone in Lilly's plans to invest in Limerick. Having graduated from the University of Limerick myself, I am delighted that Lilly has chosen the city for this major expansion of our global manufacturing footprint. I am confident that Lilly's arrival to Limerick will bring many additional benefits to the local community, the city and the region in the years ahead."
Ireland is an important European manufacturing hub for Lilly, which employs around 2,000 permanent staff in its Irish operations in County Cork, with an additional 500 outsourced and contract staff. The company's first site in Kinsale, County Cork, has grown into a high-technology manufacturing campus that makes active ingredients for Lilly medicines. It has expanded in recent years to become a center for synthetic small molecule active pharmaceutical ingredient (API) commercialisation.
In related Irish pharma sector news, Swiss major Novartis International AG (NYSE:NVS) (Basel, Switzerland) has announced that 400 jobs are to be cut at its Dublin operations as part of a larger, global restructuring. The changes will take place over the next two years at its Global Service Center, which currently employs around 1,000 staff. "Novartis recognises that announcing such an intention has a significant impact on people and creates uncertainty," the company said in a statement. "Novartis is committed to keeping associates informed in as transparent and timely a manner as possible."
In June, the company announced that in an effort to become "leaner and simpler," it would be cutting 8,000 jobs from its global workforce of 108,000 people.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
